Blue Cross and Blue Shield of Massachusetts reported just $2.2 million in net income in the third quarter as rising specialty drug prices and increased complexity of medical care dampened the insurer’s finances.
“While we are seeing signs of stability across our overall financial health, we are still operating in an exceptionally high-cost environment,” CFO Ruby Kam said Nov. 13. “Healthcare spending nationally is rising at rates we haven’t seen since the early 1980s, and here in Massachusetts, cost growth has exceeded state benchmarks for four years running.”
The company posted revenue of $2.7 billion (0.1% net margin) and an operating loss of $43.5 million in the quarter (-1.6% operating margin), along with an investment income of $45.7 million.
In Q2, BCBSMA earned $83.4 million on the same $2.7 billion in revenue (3% net margin). In the first quarter, the insurer posted a $59.6 million net income, its first profitable period after back-to-back annual losses in 2024 and 2025. The company dropped GLP-1 coverage for weight loss last year and has also been managing costs through layoffs, voluntary separations and real estate consolidation.
In October, a Health Affairs study found GLP-1 spending at the insurer rose 84% in one year and contributed as much to overall spending growth as every other retail drug combined.
Year-to-date, BCBSMA’s net income stands at $145.1 million on $8.1 billion in revenue, or a 1.8% net margin.
